Dere Willard H reported acquisition or exercise transactions in this Form 4 filing.
BIOMARIN PHARMACEUTICAL INC director Willard H. Dere received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The grant is recorded at a price of $0.00 per share, reflecting that it is a compensation award rather than a market purchase.
Following this award, Dere directly holds 46,440 shares of BioMarin common stock as reported in this filing. The footnotes clarify that the transaction represents restricted stock units, with price not applicable.
CLARK IAN T reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Ian T. Clark received an equity grant. On June 2, 2026, he was awarded 7,490 restricted stock units tied to the company’s common stock, with no cash price per unit. Following this grant, he directly holds 14,490 common shares and units in total.
Bodem Barbara W. reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical Inc. director Barbara W. Bodem received a grant of 7,490 shares of common stock in the form of restricted stock units on June 2, 2026. The award had no purchase price, indicating it was compensation rather than an open-market buy. After this grant, she directly holds 21,045 common shares.
ANDERSON ELIZABETH M reported acquisition or exercise transactions in this Form 4 filing.
BioMarin Pharmaceutical director Elizabeth M. Anderson received a stock-based compensation grant. On June 2, 2026, she was awarded 7,490 shares of Common Stock in the form of restricted stock units at no cash cost, as the price is listed as not applicable.
After this grant, Anderson directly holds 41,940 shares of BioMarin Common Stock. This is a compensation-related award, not an open-market purchase or sale, and does not reflect a discretionary trading decision.
BioMarin Pharmaceutical Inc. reported the results of its 2026 Annual Meeting of Stockholders. Stockholders approved an amendment to the company’s 2017 Equity Incentive Plan, increasing the number of common shares reserved for issuance under the plan by 7,650,000 shares.
All ten director nominees were elected to serve until the next annual meeting. Stockholders also ratified the selection of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved, on an advisory basis, the compensation of the company’s named executive officers.
BioMarin Pharmaceutical executive Cristin Hubbard reported a routine tax-related share disposition. On this Form 4, 2,318 shares of Common Stock were withheld at $50.20 per share to cover tax obligations, described as a tax-withholding disposition. After this non-market transaction, Hubbard directly holds 42,472 shares.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold shares in an open-market transaction. On May 7, 2026, he sold 3,281 shares of common stock at $53.85 per share. After this sale, he directly owns 51,818 shares of BioMarin common stock.
BMRN submitted a Form 144 notice reporting proposed sales of Common Stock through Fidelity Brokerage Services LLC on 05/07/2026. The filing lists 3,281 shares with an indicated aggregate value of $176,682.18 and references NASDAQ. It also shows recent compensation vesting and ESPP purchase items and a past sale of 6,326 shares on 02/26/2026 with value $381,937.07.
BioMarin Pharmaceutical Inc. reported lower profitability for the quarter ended March 31, 2026 while preparing for a major acquisition. Total revenues were $766.2 million, up modestly from $745.1 million, driven by higher sales of VOXZOGO, NAGLAZYME, BRINEURA and other enzyme therapies, partly offset by declines in ALDURAZYME and ROCTAVIAN after its market withdrawal.
Cost of sales rose to $195.0 million, compressing gross margin to 74.5% from 79.7%, mainly due to a $31.0 million charge tied to an unsuccessful NAGLAZYME manufacturing campaign. Research and development expense increased to $178.8 million and selling, general and administrative expense to $258.3 million, reflecting pipeline expansion and Amicus pre-close costs. Net income declined to $105.5 million, or $0.54 per diluted share, from $185.7 million.
Cash, cash equivalents and restricted cash equivalents increased to $3.07 billion, helped by liquidating investments and issuing $850.0 million of 5.5% senior notes due 2034, partly held in escrow. After quarter-end, BioMarin closed the approximately $4.8 billion all-cash acquisition of Amicus, adding GALAFOLD, POMBILITI + OPFOLDA and Phase 3 asset DMX-200, funded with cash on hand and new $2.8 billion term loans plus a $600.0 million revolving credit facility, significantly increasing long-term debt obligations.
BioMarin Pharmaceutical Inc. reported first-quarter 2026 results and raised its full-year 2026 revenue outlook. Total revenues were $766 million, up 3% year-over-year, driven by Enzyme Therapies and more patients starting VOXZOGO. GAAP net income fell to $106 million, with Non-GAAP income at $149 million, reflecting higher selling, R&D and manufacturing costs, including a $31 million NAGLAZYME manufacturing charge.
The company increased 2026 total revenue guidance to $3.825–$3.925 billion, mainly from adding GALAFOLD and POMBILITI + OPFOLDA after completing the Amicus acquisition. Enzyme Therapies revenue guidance rose by $500 million, while Non-GAAP diluted EPS guidance edged to $4.85–$5.05. Operating cash flow was $221 million in the quarter, and the company secured about $3.7 billion of new non-convertible debt to fund the Amicus transaction.